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Review Article

Craniocerebral aspergillosis in immunocompetent hosts:
Surgical perspective
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Muhammad Shahzad Shamim, Arshad A. Siddiqui, Syed Ather Enam, Ahmed Ali Shah,
Rashid Jooma*, Saleha Anwar**
Division of Neurosurgery, The Aga Khan University, *Department of Neurosurgery, Jinnah Postgraduate Medical Centre, **Department of
Radiology, Liaquat National Postgraduate Medical Centre, Karachi, Pakistan

Craniocerebral aspergillosis is a rare but dangerous variety
of central nervous system infections. Surgery is being widely
recognized as the cornerstone of management. Due to the
rarity of the disease, difÞculty and delay in diagnosis and
poor outcome, there is very little in the literature regarding
the various surgical strategies that may be adopted in these
patients. Early aggressive surgery followed by chemotherapy
offers the best chances. Surgical planning would depend upon
the type and location of the disease process as well as the
condition of the patient. Perioperative care holds immense
importance and knowledge of possible complications is
essential. Aspergillosis of the central nervous system is difÞcult
to diagnose and equally difÞcult to treat. Surgery remains the
cornerstone of management followed by systemic antifungal
medications. Results are better in immunocompetent patients
as compared to those who are immunocompromised.
Key words: Aspergillosis, fungal infections, immunocompetent
hosts

the CNS.[2-8] The reason for this can be the increasing
number of immunocompromised patients due to the
growing epidemic of acquired immunodeficiency
syndrome (AIDS), chronic granulomatous diseases,
autoimmune diseases or due to the increasing population
of patients having had solid organ transplants and
on immunosuppressants. The reason can also be
the widespread availability of neuroimaging i.e.
computerized tomography (CT) and MRI scanning
which has lead to earlier diagnosis and thus earlier
referrals to neurosurgical centers.
Of late a newer class of patients have been recognized,
those who are apparently immunocompetent, harboring
CNS fungal infections. These cases present an
interesting diagnostic dilemma for the neurosurgeons
and neuroradiologists, as neither the clinical nor the
imaging features of CNS fungal infections are truly
diagnostic of the disease and with the patient being
immunocompetent, the possibility of fungal infection
is considered low on the list of differentials.[9]

Pathophysiology

Surgical treatment of fungal infections of the central
nervous system (CNS) has always been a challenge to
the neurosurgeon. The CNS may be involved primarily,
as primary intracranial infection or secondarily through
hematogenous spread of the disease from elsewhere.
Fungal infection can also spread directly from adjacent
structures, notably sinonasal disease. Fungal infection
of the CNS is extremely dangerous, affecting mainly the
immunocompromised hosts with a reported mortality of
almost 100% in earlier literature. Fortunately, the disease
is relatively uncommon, accounting for less than five
per cent of all CNS infections and was even referred to
as “almost always a clinical surprise” in a recent review
by Nadkarni and Goel.[1] However, recently we have
noticed a rise in the reporting of fungal infections of

Aspergillus fumigatus is the most commonly identified
human pathogen, especially in immunocompromised
hosts. Since Aspergillus spores are commensals in
the respiratory tract and external auditory canal, it
is understandable why maxillary sinusitis and lungs
are the most common sites of primary aspergillus
infection. Primary aspergillosis of the paranasal sinus
has been classically described to be of two kinds; either
noninvasive (also called allergic Aspergillus sinusitis) or
invasive. Infection may reach the CNS either through
direct spread or hematogenous spread. Erosion of bone is
not always necessary for direct intracranial extension as
the fungus has the propensity to spread along vessels that
serve as direct channels for the seeding of aspergilli.
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been shown to have a tendency for invasion of the
walls of both small and large blood vessels, which may
lead to either thrombosis and subsequent infarction or
equally dangerous hemorrhage. The organism can also
spread beyond the vessel walls and form abscesses in
the altered brain tissue.

Radiological Diagnosis
The findings in the conventional CT scan and magnetic
resonance (MR) imaging are frequently minimal or absent
in the hyperacute stage of CNS aspergillosis.[17,18] On CT
scanning, a number of features have been reported,
though none are specific for fungal disease. Presence
of a hyperdense mass lesion in the sinuses along with
bony expansion or erosion of sinus walls and/or cranial
base is frequently observed in patients [Figures 1 and
2] having intracranial aspergillosis of sinonasal origin
i.e. the invasive variety of aspergillosis.[2,12] Abscesses
demonstrate ring or homogenous enhancement along
with mass effect. At times there may be slight or
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Single or multiple abscesses with marked vascular
invasion with or without thrombosis is the hallmark
of cerebral aspergillosis on pathologic examination.
Aspergillus has a tendency to invade vessels producing
a sort of necrotizing angiitis leading to secondary
thrombosis with or without hemorrhage. Fungal hyphae
are found in large, intermediate and small blood vessels
with invasion through vascular walls into adjacent
tissue. The evolving hemorrhagic infarcts later convert
into septic infarcts with associated abscesses and
cerebritis. The mechanism of damage at the cellular
level in cerebral Aspergillus lesions has been recently
shown to be due to secretion of various necrotizing
factors with toxic and lytic activity toward neurons and
glial cells.[10] Although the mechanism of invasiveness
in immunologically competent hosts remains unclear, it
is possibly caused by qualitative cellular or sub-cellular
immunodeficiency that is either unrecognized or poorly
characterized. Nevertheless, formation of granulomas
and the presence of epithelioid and multinucleate giant
cells in these patients indicate at least some integrity
of immune response. Purulent lesions may be chronic
and have a tendency towards fibrosis and granuloma
formation. In purulent lesions, pus is seen in the
centre of the abscesses with abundant polymorphs at
the periphery. Granulomas consist of lymphocytes,
plasma cells and fungal hyphae.[11] In summary, brain
abscess, epidural abscess, vasculitis, stroke-like illness,
granulomatous mass and meningitis are the various
types of CNS aspergillosis.[12]

Presentation

Classically, craniocerebral aspergillosis should be
considered in any patient known or suspected to be
immunocompromised, presenting with signs, symptoms
and radiological features of space-occupying lesion
with or without a preceding history of nasal blockade/
discharge. Multiple studies have described a variety
of presenting symptoms such as nasal stuffiness,
headache, peri-orbital pain, vomiting, convulsions,
hemiparesis, cranial nerve deficits (diplopia/anosmia),
proptosis, sensory impairment, dysarthria, lethargy,
impaired consciousness and seizures with or without
fever and rarely, ear discharge.[3,13,14] In patients with
paranasal sinus disease orbital extension with proptosis,
ophthalmoplegia, visual deterioration (which may
lead to total monocular blindness) and chemosis may
occur. Another feature usually associated with these
patients is hypertelorism. Features typical of meningitis
and subarachnoid hemorrhage resulting from mycotic
aneurysms may also manifest.[11,15] The disease is usually
slowly progressive and symptoms may persist for
months. Alternatively, patients may also present acutely
with cerebral infarctions or hemorrhage, a manifestation
of vascular invasion of the fungus.[16] Aspergillosis has
Neurology India | July-September 2007 | Vol 55 | Issue 3

Figure 1: CT scan coronal sections showing Aspergillus involvement
of paranasal sinuses with intra-cranial extension, typical of invasive
aspergillosis. Patient was immunocompetent

Figure 2: CT scan coronal section showing sinonasal disease eroding the
cribiform plate and extending intracrially. Patient was immunocompetent
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Figures 3, 4, 5: Axial T1 weighted image showing hypo-intense right frontoparietal lesion. T2 weighted image of same showing
hyper-intense signals with patchy iso to hypo-intensities. There is signiÞcant edema and mass effect. On contrast administration,
the lesion showed patchy enhancement, mainly at the center of the lesion. These Þndings are not typical of aspergillus disease,
although the pathology conÞrmed this to be aspergillosis. Patient was immunocompetent

even no contrast enhancement [Figures 3-5]. Early
hemorrhage or infarctions are other features associated
with aspergillosis and should raise the suspicion in
immunocompromised hosts. Overall, CT scanning
not only helps in the diagnosis but is also helpful in
providing a convenient way to monitor the patient’s
response to antimicrobial therapy.
On MR imaging, the classical description is that of an
irregular space-occupying mass lesion having hypo- to
iso-intense signals on T1-weighted images [Figure 6],
extremely low signals on T2-weighted images with
either bright homogenous enhancement on postgadolinium T1 weighted images or ring enhancement
pattern. At times a thick irregular wall of mass lesions
on CT and MR imaging is apparent, which indicates a
competent host defense mechanism that is attempting
to isolate or encapsulate the offending organisms. The
differential diagnosis of multiple brain lesions in an

Figure 6: Axial T1 weighted image with gadolinium enhancement
showing nasal and left orbital involvement with left proptosis. Patient
also has a left temporal ring-enhancing abscess in the absence of bony
erosion. The lesions turned out to be Aspergillus in etiology. Patient was
immunocompetent
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immunocompromised patient includes lymphoma,
metastatic disease, septic emboli, tuberculomas and
multiple infarcts. It may be mentioned here, that the
diagnosis of aspergillosis in all cases is supported with
the involvement of paranasal sinuses but as for all
reported features, it is also not diagnostic on its own.

Surgical Management

There are no specific treatment guidelines for
intracranial aspergillosis, as detailed data on patient
survival is only available from case reports and case
series.[19,20] Despite newer, safer and more effective
antifungal medications, it is generally agreed that the
cornerstone of treatment remains surgical excision.
This is based largely on reports of personal experience;
and more recently on the basis of a multifactorial risk
analysis done by Schwartz et al. on the data of a study
population comprising mainly immunocompromised
patients on variconazole therapy, which suggested
improved outcomes in patients who had undergone
neurosurgical intervention.[19] Besides, there are very few
reports of patients surviving CNS aspergillosis on medical
treatment alone. [20,21] It cannot be overemphasized
that surgical excision must always be followed by
aggressive antifungal chemotherapy to achieve the best
response.[19,22-26] It has been observed that radical surgery
done early and as a first procedure is better than repeated
attempts at sub-radical resection.[27] We have reported
our own experience from two large university hospitals
of Karachi and in our experience radical excision of
fungal mass does not seem to be necessary.[2] Radical
surgery involving risks of morbidity seems excessive
for an infective process. Sub-radical excision aimed at
establishing diagnosis and reducing disease burden,
in process, avoiding the risks of permanent iatrogenic
neurological deficits, followed by systemic antifungal
Neurology India | July-September 2007 | Vol 55 | Issue 3
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requires multidisciplinary team approach involving
the neurosurgeon, ENT surgeon, ophthalmologist,
maxillofacial surgeon, neuroradiologist, intensivist,
infectious disease expert and clinical pharmacist.
Perioperative management of these patients requires
special mentioning. It is a critical time period which
starts from the time of incision and lasts almost a week or
even longer. It is the most difficult part of management
and from our experience we have learned that it requires
more vigilance and aggression than perhaps the surgery
itself. The Aspergillus shows a peculiar response to
surgery, not reported for any other disease process.
The disease process which may have been present for
some time, flares up postoperatively assuming a rapidly
fulminant course if not dealt with immediately and
aggressively. The hallmark of this unusual response is
high-grade fever, tachycardia and rapidly increasing
diffuse cerebral edema causing a potentially fatal rise in
intracranial pressure refractory to medical management,
a series of events that we refer to as the “Forest Fire
Phenomenon”. The reason for this unique stormy
postoperative course is incompletely understood but may
be explained on the basis of either the patient becoming
immunocompromised secondary to surgery or due to
the manipulation of organism catalyzing the stimulation
of previously quiescent fungi. This eventually leads
to widespread catastrophic angio-invasion causing
massive cerebral edema as well as possibly massive
release of cytokines. Another possibility is that of acute
Aspergillus meningo-encephalitis which may also lead
to diffuse cerebral edema. The organism’s response to
surgery is sometimes apparent even intraoperatively
as the patient’s body temperature begins to rise, at
times beyond 40 degrees and the brain starts to swell
up rapidly. We recommend that the surgery for fungal
infections be of shortest possible duration, yet as
aggressive as possible. At the slightest intraoperative
impression of increasing brain swelling, serious thought
should be given to keeping the bone flap off and doing
duroplasty, thus allowing the brain to further swell up
without the risk of herniation. Indeed, we have had to
take the patient back to the operating room at times twice
within the first 48h to deal with the increasing brain
swelling which is refractory to medical management.
As a result, we now routinely monitor intracranial
pressure in these patients postoperatively with an
intra-ventricular catheter, keep them in intensive care
units and manage them with high doses of Mannitol.
The role of steroids is questionable, as hypothetically it
would further compromise the patient’s immune status
but on the other hand, it may help control the edema
on virtue of its effect on the vasogenic component of
cerebral edema. There is no evidence which supports
its use or avoidance and the decision would rest with
the neurosurgeon’s comfort level. The patient is kept
intubated and intermittently sedated using Propofol
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therapy seems to be a better course of action. However,
whenever faced with a surgically removable lesion in a
noneloquent area, the best plan would be to eradicate
the lesion completely rather than sub-radical resection.
Sub-radical resection may be reserved for lesions which
are only partially resectable. Obviously, in a lesion
occupying an eloquent area, where iatrogenic permanent
neurological deficits seem inevitable even if sub-radical
excision is attempted, a biopsy would suffice.
A similar approach is advisable in case of cerebral
aspergillus abscesses. These should be excised
completely if there is no risk of further neurological
deficits as complete excision has been shown to improve
outcome.[28] Even lobectomy, in patients with a single
aspergillus abscess is an acceptable surgical option when
noneloquent areas of the brain are involved. In the series
reported by Nadkarni and Goel, four of seven patients
with cerebral aspergillosis who survived, complete
surgical resection of brain abscess was accomplished.[1]
On the other hand, when eloquent brain areas are
found to harbor an aspergillus abscess, aspiration
may be the only surgical option which may be done
more precisely under neuronavigation or stereotactic
guidance, especially if the abscesses are deep-seated. It
should be borne in mind that abscess fluid may not be
diagnostic in all cases as fungal hyphae are abundant
largely in the abscess rim rather than the necrotic center.
For best diagnostic yields, multiple specimens from both
the rim and center should be sought. This procedure
may also be carried out in awake patients under local
anesthesia using burr hole or mini craniotomy. Necrotic
brain tissue and granulomas are likewise subjected to
radical debridement which would theoretically enhance
antibiotic penetration and reduce fungal load by removal
of debris. Extradural disease is less complicated to
deal with and should be treated according to basic
neurosurgical principles established for other forms of
exradural abscesses, followed of course by antifungal
therapy.
Whenever the nasal passages are suspected to be
involved, we strongly recommend thorough clearance
of nasal passages, thereby depriving the fungus of a
potential microaerophilic environment otherwise suitable
for its proliferation. For this purpose, we have benefited
greatly from endoscopic sinus surgery, which requires
the help of ENT surgeons. The procedure may need to be
repeated more than once for adequate clearance of nasal
passages and sinuses. When the globe is also involved
the patient mostly does not have vision in that eye and
enucleation should be considered and discussed with
the patient. This becomes even more difficult when the
globe is clearly affected by the fungus but the vision is
intact. In such cases, preservation of the eye with serial
monitoring with MRI and objective ophthalmological
examinations such as perimetry and visual evoked
potentials may be considered. The management therefore
Neurology India | July-September 2007 | Vol 55 | Issue 3
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pressure (CVP) of 8-10 is desirable, keeping the patient
euvolemic. Persistently low CVP refractory to fluid
challenges suggests systemic vasodilatation secondary
to fungal sepsis and should be dealt with systemic
vasoconstrictors. We generally prefer nor-epinephrine
for this which is started at the lowest possible dose and
adjusted according to the patient’s need. Our choice of
fluid was isotonic saline (0.9%) as theoretically it has the
least effect on ICP. In case of worsening ICP, hypertonic
saline may also be considered. The urine output must
be maintained at above 1-2 ml/kg body weight and in
case of fall in urine output, rise in blood urea, nitrogen
and creatinine levels, hemodyalisis may need to be
considered as an alternate to discontinuing nephrotoxic
antifungal medications. The multidisciplinary team
approach is most important in this timeframe. Cardiac
arrhythmias may be precipitated due to both sepsis
and electrolyte imbalance and in a patient with a
cardiac history or showing abnormal rhythm, a SwanGanz catheter may be required depending upon the
internist’s decision. The neurosurgery team must
always be involved in all decisions, for at times a central
complication may manifest as a systemic one and may
be missed by those not trained in neuro-intensive
care. We routinely keep our patients on anti-epileptic
medications starting preoperatively, although there is
no evidence to suggest any benefit of prophylactic antiepileptic medications. Our argument for anti-epileptic
drugs is based on the extremely critical condition of
these patients postoperatively and any factor which may
increase the intracranial pressure during this time such
as a seizure may prove detrimental. Interestingly, such
maneuvers are not required in patients having extradural
disease alone. It is only when the fungus involves brain
parenchyma and during surgery the dura is opened that
we see the “Forest Fire Phenomenon”.
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which also helps in decreasing intracranial pressure.
Continuous sedation is avoided to allow observation of
progressive neurological deficits. Repeat neuro-imaging
studies at appropriate intervals may be used to monitor
the intracranial complications in the postoperative
phase. This helps in comparing the extent of cerebral
edema and also in ruling out acute hemorrhage
and hydrocephalus, two established postoperative
complications as we shall discuss later. At the slightest
hint of increasing cerebral edema and impending
herniation, a decompressive craniotomy is undertaken.
Decompression may just involve removing the bone flap
with or without duroplasty, frontal lobectomy, temporal
lobectomy with or without uncusectomy or all of the
mentioned procedures depending upon the degree of
swelling. The craniotomy may need to be extended
under such circumstances to increase the size of bone
flap which is to be removed. The bone flap may be
saved in the patient’s anterior abdominal wall which
has the advantage of showing early signs of infection
and also convenience if the patient needs to be shifted to
another hospital. We, however, preserve our bone flaps
sterilized in subfreezing temperatures in a dedicated
bone bank. We do not see any point in discarding the
bone flap and later using acrylic for cranioplasty in such
patients, however individual practices may vary. If the
bone flap is in close proximity of fungal mass, alternate
closure methods may be considered. Autoclaving the
bone before putting it back is also an option under such
circumstances.
In the postoperative period, special attention should
be given to the patient’s metabolic profile, as the patient
is under the influence of a number of factors which may
lead to metabolic derangements and may jeopardize
the entire management. These factors include fungal
sepsis secondary to manipulation of the fungal mass,
high-grade fever and possible risk of acute renal failure
due to combined insults from sepsis, mannitol and most
importantly the antifungal medications. Electrolyte
imbalance may occur acutely and all electrolytes
need to be repeated and corrected every two to four
hours. Patient is kept on regular high-dose analgesics
and anti-pyretic to avoid any increase in intra-cranial
pressure (ICP) secondary to pain or fever. We tend
to avoid non-steroidal anti-inflammatory drugs for
the possible nephrotoxicity and platelet dysfunction
despite their superiority in controlling both fever and
pain. Continuous invasive blood pressure monitoring
using an arterial line is mandatory. The mean arterial
pressure (MAP) is kept at around 100-110 as too low may
induce infarctions in the swollen brain and too high may
further worsen the ICP. Any rapid rise in MAP and ICP
should suggest ongoing complications. Fluid balance
is also critical as too much fluid may increase cerebral
edema and too little may worsen renal failure. A central
venous line is therefore essential and a central venous
278

Adjunct Medical Management

The medical management of intracranial fungal
infections should not be considered separately
from the surgical management. It is complementary
to surgery and should be considered an essential
component of the overall management. For a long
time, the standard therapeutic regimen for cerebral
aspergillosis following surgery remained intravenously
administered amphotericin B combined with or
followed by flucytosine or itraconazole.[2,23-32] Since
the introduction of itraconazole, the first azole with
significant activity against Aspergillus, many multicenter
clinical trials have proven its efficacy, in combination
or in sequential regimen.[33-38] Two newer parenteral
antifungal medications (echinocandins) caspofungin
and micafungin, which were initially studied for their
effectiveness against Candidiasis are also under scrutiny.
However, all of the aforementioned medications are
Neurology India | July-September 2007 | Vol 55 | Issue 3
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Besides the general complications anticipated after
any major cranial procedure and the adverse effects
described for the antifungal medications, some specific
complications reported for these patients include
massive anaphylaxis, meningitis, mycotic aneurysm
formation, intracerebral hemorrhage, subarachnoid
hemorrhage and hydrocephalus. Hydrocephalus is
usually of the communicating type, although noncommunicating type may also occur. Patients need to be
serially monitored with CT scans for this complication
which can easily be dealt with ventriculoperitoneal
shunt. Perhaps the two most catastrophic complications,
both unusual in etiology are; widespread multifocal
dissemination in the brain parenchyma/ ventricles
and vascular infarcts involving major cerebral vessels,
which may be remote from the site of surgery.[2,53-59]
Such patients show a stormy postoperative course and
may require major debulking or even decompressive
craniotomy to prevent herniation due to rapidly
increasing intracranial pressures. Despite these efforts,
patients may still succumb to the disease and those who
survive, will have crippling neurological deficits. Both
of these complications are attributable to subclinical or
occult angioinvasion, which is a hallmark of the disease
as discussed in previous sections.
Outcome of craniocerebral aspergillosis is different in
immunosuppressed and apparently immunocompetent
hosts.[23,29] In immunocompromised hosts mortality is
reported to reach more than 95% and even 100% in
patients with underlying malignancies.[60] In apparently
immunocompetent hosts reported mortality varies from
center to center, but ranges from 40-80%.[1,2] Patients
harboring mainly sinonasal disease with only orbital
and/or cranial base bony invasion/destruction, carry a
very good prognosis (mortality < 20%).[2] Outcome in
extradural aspergillosis is much better than in patients
with intracerebral involvement.[2] The dismal prognosis
should nevertheless, not discourage the care providers
from aggressive management of these patients as success
stories are also frequently encountered.
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used mainly as adjuncts to surgical management, as
despite improving outcomes compared to control
groups; these show relatively poor penetration into the
CNS. Amphotericin B, itraconazole and caspofungin
all show negligible levels in CSF or brain tissue.[39-41] A
newer triazole, voriconazole is becoming increasingly
popular and has been shown to have a CSF to plasma
ratio of 0.22 to 1, as well as high brain tissue levels in
autopsy studies.[19-42] In several studies and one large
randomized trial conducted by Herbrecht et al. recently,
voriconazole has proven to be more effective and less
toxic than amphotericin B and has since become the
first line of treatment of aspergillosis.[12,43-47] Recently,
Clemons et al. supported the potential of combination
therapy as a mechanism to improve the outcome in CNS
aspergillosis, showing that a combination of suboptimal
doses of liposomal amphotericin B and voriconazole
given concurrently had a significantly better efficacy
in comparison with either monotherapy.[48] In addition,
liposomal amphotericin B in combination with
caspofungin and micafungin also showed strong trends
towards improved efficacy.
As a protocol, we now administer preoperative oral
itraconazole empirically in all our patients in whom
a diagnosis of cerebral aspergillosis is suspected on
the basis of clinical suspicion or neuroradiological
features. This prophylactic regimen in our published
experience leads to improved outcomes and prolonged
survival, even though a direct causal relationship has
not been effectively established.[2] Some authors have
similarly proposed preoperative amphotericin B as a
potential factor for improving prognosis.[49,50] As for all
rare diseases, it is not possible to scientifically comment
upon the comparative efficacy of these prophylactic
medications based entirely on personal experiences. A
systemic review of the literature with the sole purpose
of establishing the role of one or the other prophylactic
antifungal medication is needed. It may be argued
here that although the effectiveness of any of these
medications preoperatively is not proven scientifically,
they have certainly not been proven to be harmful.
Preoperative oral itraconazole as part of the protocol
for the management of all such patients should be
considered seriously. A few anecdotal reports have been
published that describe treatment with intracavitary
amphotericin B.[20,21,51,52] In our opinion, this should only
be considered as a last resort as there is no evidence of
the safety and efficacy of the drug when directly instilled
into the ventricles or the abscess cavity.

Complications and Prognosis
The unpredictable nature of the disease is apparent
not only in its clinical presentation, radiological
appearance, clinical course and response to treatment,
but also when dealing with the postoperative patient.
Neurology India | July-September 2007 | Vol 55 | Issue 3

Conclusion
Aspergillus infection of the CNS is an uncommon clinical
entity, affecting mainly the immunocompromised. The
disease presents in a number of unusual ways and
although a multitude of clinical, biochemical and
radiological features have been described, the diagnosis
remains elusive. The problem is further compounded
when the host is apparently immunocompetent, which
lowers the clinical suspicion. Surgery followed by
systemic antifungal medications offers the best hope for
survival. Despite better understanding of the offending
organism, pathophysiology, clinical course and
development of more effective antifungal medications,
the prognosis remains poor. High index of suspicion,
279
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early diagnosis and aggressive surgical management,
followed by medical therapy, by an interdisciplinary
team, may help to improve outcomes.
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